Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
- Professor of Musculo- Skeletal Pathology
- Research Department of Pathology
- Cancer Institute
- Faculty of Medical Sciences
Adrienne received her medical degree from the Royal College of Surgeons in Ireland and undertook her PhD at the University of London in 1990 while she was a Medical Research Council Training Fellow at St George's Hospital Medical School in London. She became a senior lecturer and honorary consultant pathologist at Imperial College London, and later moved to University College London, and now practices clinical pathology at the Royal National Orthopaedic Hospital. Adrienne was elected as Professor of Musculoskeletal Pathology at UCL’s Cancer Institute in 2004. Adrienne is the Meeting Secretary of Pathological Society of Great Britain and Ireland, and a trustee or member of the Sarcoma UK, The Jean Shanks Foundation, and The Chordoma Foundation (USA). Her research interests focus on reclassifying bone and soft tissue tumours using molecular signatures which she then translates into clinical practice, and uses for stratifying patients for treatment. She was the co-lead of the International Cancer Genome Consortium bone tumour project (2010-2015).
In 2017 she became a senior NIHR Fellow, and was awarded the Goudie for her contribution to pathological science and the understanding of disease mechanisms. She was also awarded the William Gerald Award by the Department of Pathology Memorial Sloan Kettering Cancer Centre in recognition for her contribution to research in caner pathology.




Adrienne's research programme focuses on identifying the genetic alterations involved in the development and progression of bone and soft tissue tumours, and translating the findings into the diagnostic service. Correlation of these abnormalities with the histopathology improves diagnostic accuracy, allows sub-classification of neoplastic disease and helps to predict therapy, and outcome / survival. She identified that brachyury expression is the hallmark of chordoma, a biomarker which is now employed universally in the diagnosis of this tumour; she was the first to report IDH1 and IDH2 mutations in cartilaginous tumours and demonstrated that this mutation was pivotal to the development of Ollier and Maffucci syndrome. She also reported the recurrent H3F3 mutations in giant cell tumour of bone and chondroblastoma. A close collaboration with the Cancer Genome Team in the Wellcome Trust Cancer Institute resulted in the generation of the genomic landscapes of several bone tumour types including chondrosarcoma, osteosarcoma, chordoma, giant cell tumour of bone, and chondroblastoma. Adrienne has worked closely with patients groups to bring about her research.
Postgraduate: Advanced Histopathology Course in the East of England Deanery; Thames Deanery Bone and Soft Tissue Teaching for SHOs and SpRs; World Association of Societies of Pathology and Laboratory Medicine (WASPaLM), Penang 2008 International Update on bone tumours; Association of Societies of Pathology and Laboratory Medicine (WASPaLM), Update Chandigarh 2010 International Update on soft tissue tumours; Plenary lecture May 2007 & 2008. Molecular genetic events in fibro-osseous and osteoclast-rich lesions of the jaw. The 14th International Congress of Oral Pathology and Medicine. San Francisco. June 2008. Plenary lecture and Seminar. Crucial molecular genetic events in chordoma plenary lectury 43rd Annual Musculoskeletal Tumor Meeting of the Japanese Orthopaedic Association, Shinjuku, Tokyo, Japan, June 2010.
Consultant histopathologist | Histopathology | Royal National Orthopaedic Hospital, United Kingdom | |
Head of Department of Pathology | Pathology | UCL Cancer Institute, United Kingdom |
1990 | Doctor of Philosophy | University of London | |
1981 | Bachelor of Medicine | Royal College of Surgeons in Ireland |